UK biotech sector sets new record with more than £1bn investment in Q3There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, Share XUK biotech sector sets new record with more than £1bn investment in Q3https://pharmaphorum.com/news/uk-biotech-sector-sets-new-record-with-more-than-1bn-investment-in-q3/
MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOCompass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy Share XMindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOhttps://pharmaphorum.com/news/mindmed-aims-for-nasdaq-listing-after-compass-magic-mushroom-fuelled-ipo/
Compass plans $100m IPO to fund magic mushroom depression drugUK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its Share XCompass plans $100m IPO to fund magic mushroom depression drughttps://pharmaphorum.com/news/compass-plans-100m-ipo-to-fund-magic-mushroom-depression-drug/
Inozyme plans $75m IPO as it heads for clinic with rare bone diseases drugUS biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a Share XInozyme plans $75m IPO as it heads for clinic with rare bone diseases drughttps://pharmaphorum.com/news/inozyme-plans-75-ipo-as-it-heads-for-clinic-with-rare-bone-diseases-drug/
Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&DCalifornia biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last Share XPoseida Therapeutics aims for $115m stock market launch to fund CAR-T R&Dhttps://pharmaphorum.com/news/poseida-therapeutics/
Royalty Pharma shares surge 59% after $2.2 billion IPOBiopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised Share XRoyalty Pharma shares surge 59% after $2.2 billion IPOhttps://pharmaphorum.com/news/royalty-pharma-shares-surge-59-after-2-2-billion-ipo/
Royalty Pharma plans largest IPO of the year so farRoyalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. Share XRoyalty Pharma plans largest IPO of the year so farhttps://pharmaphorum.com/news/royalty-pharma-plans-largest-ipo-of-the-year-so-far/
California’s AMT is latest biotech aiming to go public in pandemic IPO crazeCalifornia’s Applied Molecular Transport has become the latest biotech to go for an IPO during the pandemic, aiming Share XCalifornia’s AMT is latest biotech aiming to go public in pandemic IPO crazehttps://pharmaphorum.com/news/californias-amt/
ADC Therapeutics sets terms for $125m IPOSwiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop Share XADC Therapeutics sets terms for $125m IPOhttps://pharmaphorum.com/news/adc-therapeutics-sets-terms-for-125m-ipo/
